Quantcast
Last updated on April 25, 2014 at 5:51 EDT

Latest ClinicalTrials.gov Stories

2011-02-04 01:30:00

WAYNE, N.J., Feb. 4, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. announced today that its investigational compound regorafenib (BAY 73-4506) has been granted orphan drug status for the treatment of patients with gastrointestinal stromal tumors (GIST) by the U.S. Food and Drug Administration (FDA). Regorafenib is an investigational agent and is not approved by the FDA, the European Medicines Agency (EMA) or other Health Authorities. "This is an important step in the overall...

2010-12-06 06:00:00

Company to discuss interim results from Phase I/II trial of CYT387 being presented today at the 52(nd) American Society of Hematology Annual Meeting ORLANDO, Dec. 6 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI; TSX: YM) announced that it will hold an analyst meeting and conference call today at 12:30pm ET to discuss the interim results from the first 60 patients enrolled in the 140 patient Phase I/II trial of its JAK1/JAK2 inhibitor, CYT387, in myelofibrosis. An oral...

2010-11-18 07:27:00

MISSISSAUGA, ON, Nov. 18 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), today reported that the Phase I/II clinical trial for its orally available JAK1/JAK2 inhibitor, CYT387, in patients with myelofibrosis has been expanded to five sites. Of the additional sites, the Stanford Cancer Center (Stanford, California) under Principal Investigator Jason Gotlib, MD has already commenced enrolling patients. YM also announced that the trial protocol has been extended to allow...

2010-11-04 05:00:00

ANN ARBOR, Mich., Nov. 4, 2010 /PRNewswire-FirstCall/ -- Adeona Pharmaceuticals, Inc. (AMEX: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today that it was awarded two grants totaling $488,959 under the Qualifying Therapeutic Discovery Project (QTDP) Program to support the Company's Alzheimer's disease and multiple sclerosis programs currently in clinical testing. These grants represent approximately 38% of the Company's total research...

2010-08-12 12:52:00

Deadly Lung Disease has no FDA Approved Therapies, Desperately Needs Treatment Options SAN JOSE, Calif., Aug. 12 /PRNewswire-USNewswire/ -- The Coalition for Pulmonary Fibrosis (CPF) is urging the more than 128,000 people known to suffer from the deadly lung disease, pulmonary fibrosis (PF), to consider clinical trials, including two new ones funded by the National Institutes of Health (NIH). Clinical trials of potential drug therapies are critical to the discovery of treatments for any...

2010-08-02 18:34:00

Comprehensive study of outcome reporting taps ClinicalTrials.gov BOSTON, Aug. 2 /PRNewswire-USNewswire/ -- When published results are systematically tracked for drug trials registered with ClinicalTrials.gov, those from industry-funded trials are the likeliest to be favorable to the drug in question, report researchers at Children's Hospital Boston. Publishing in the August 3 issue of the Annals of Internal Medicine, the researchers call for more public disclosure about clinical drug...

2010-07-23 10:10:00

HERNDON, Va., July 23 /PRNewswire-USNewswire/ -- BHR Pharma, LLC (BHR) announced today that the first patient has been enrolled in its SyNAPSe study (www.synapse-trial.com), a global, Phase 3, pivotal trial to evaluate the safety and effectiveness of its intravenous progesterone infusion product (BHR-100) as a neuroprotective agent for treating severe (Glasgow Coma Scale scores of 4-8) traumatic brain injury (TBI) patients. The study will randomize approximately 1,200 patients at more than...

2010-07-19 09:11:00

MONTREAL and HONG KONG, China, July 19 /PRNewswire/ - Aegera Therapeutics Inc. released today encouraging survival data from the Phase 1 portion of its Phase 1-2 Study of the novel targeted therapeutic, AEG35156, given in combination with sorafenib in patients with advanced hepatocellular carcinoma (primary liver cancer). This study, entitled "A Phase 1-2, Open-Label Study of The X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination with Sorafenib in Patients With Advanced...

2010-06-15 07:38:00

WASHINGTON, June 15 /PRNewswire/ -- WHAT: Sparta Systems, Inc., the maker of TrackWise(®) software and the market leader in enterprise quality and compliance management solutions, today announced its upcoming presentation at DIA's Annual Meeting on Wednesday, June 16, 2010 from 12:00 p.m. -1:30 p.m. The session will outline a simple process for businesses to automate compliance with the FDA's ClinicalTrials.gov portal and demonstrate real-life examples of best practices...

2010-06-14 08:00:00

WASHINGTON, June 14 /PRNewswire/ -- DIA Annual Meeting -- Virtify, Inc. today announced the upcoming release of its new Clinical Trials Registration & Results software product, CTRR Enterprise 2.0, part of the Virtify Enterprise Content Compliance (ECC) software suite. CTRR Enterprise 2.0 is the first and only disclosure solution that automates compliance through dynamic, real-time validation of more than 5,200 built-in rules derived from www.clinicaltrials.gov, the FDAAA-mandated...